Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Sotatercept in the Treatment of Methamphetamine-Associated Pulmonary Arterial Hypertension (METH-FOCUS)

11 november 2026 bijgewerkt door: Jeffrey Robinson, Oregon Health and Science University

Methamphetamine-Associated PAH: Early Therapy With Sotatercept - Feasibility and Outcomes in Clinical Use Study (METH-FOCUS)

The goal of this clinical trial is to find out whether sotatercept, an FDA-approved medication for people with pulmonary arterial hypertension (PAH), can improve health outcomes for people with PAH due to use of methamphetamine. The main question it aims to answer is whether sotatercept added to standard background therapy and addiction medicine services will improve treatment response as measured by:

  • Echocardiographic measurements of pulmonary hypertension
  • Change in 6-minute walk distance (6MWD)
  • Change in categorization of disease (World Health Organization Functional Class, WHO FC)
  • Quality of life improvements

Participants will need to adhere to their standard PAH therapy as well as the prescribed sotatercept, as well as actively engaging with addiction medicine services. They will complete the following activities:

  • Physical exam
  • Labs including drug screening
  • Pulmonary function testing (PFT)
  • Exercise testing (6MWD)
  • Echocardiography
  • Right heart catheterization (RHC)
  • Questionnaires related to their disease

Participants will be in the study for about six months.

Studie Overzicht

Toestand

Nog niet aan het werven

Interventie / Behandeling

Studietype

Ingrijpend

Inschrijving (Geschat)

20

Fase

  • Fase 4

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

  • Naam: Samantha Ruimy, MS
  • Telefoonnummer: 503-494-0724
  • E-mail: ruimy@ohsu.edu

Studie Contact Back-up

  • Naam: Allyson Knapper, MD
  • Telefoonnummer: 503-494-5531
  • E-mail: knapper@ohsu.edu

Studie Locaties

    • Hawaii
      • Honolulu, Hawaii, Verenigde Staten, 96813
        • The Queen's Medical Center
        • Contact:
        • Hoofdonderzoeker:
          • Gehan Devendra, MD
    • Oregon
      • Portland, Oregon, Verenigde Staten, 97239
        • Oregon Health & Science University
        • Contact:
        • Contact:
          • Samantha Ruimy, MS
          • Telefoonnummer: 5034940724
          • E-mail: ruimy@ohsu.edu
        • Hoofdonderzoeker:
          • Jeffrey C Robinson, MD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Age ≥ 18 years
  • Documented diagnostic right heart catheterization (RHC) within 12 months of screening documenting a minimum mean PA pressure of 20 mmHg, PVR of ≥ 2 Wood units and pulmonary artery wedge pressure (PAWP) or left ventricular end-diastolic pressure (LVEDP) of ≤ 15 mmHg, with the diagnosis of Meth-APAH as defined by patient verbally confirming exposure or having positive toxicology testing for methamphetamine within 5 years of PAH diagnosis
  • Symptomatic PAH classified as WHO FC II or III
  • Diagnosis of PAH within 12 months of screening and on stable doses of a ERA and PDE5i combination of background PAH therapies and diuretics (if any) for at least 90 days prior to screening
  • 6MWD ≥ 150 m completed at screening visit
  • Females of childbearing potential must meet the following criteria: Have 2 negative urine or serum pregnancy tests as verified by the investigator during the Screening Period; Agree to ongoing pregnancy testing (either urine or serum) during the course of the study and until 8 weeks after the last dose of the study drug; If sexually active with a male partner, use highly effective contraception without interruption for at least 28 days prior to starting the investigational product AND agree to use the same highly effective contraception in combination with a barrier method during the study (including dose interruptions), and for 16 weeks (112 days) after discontinuation of study treatment; Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 16 weeks (112 days) after the last dose of study treatment
  • Male participants must meet the following criteria: Agree to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 16 weeks (112 days) following investigational product discontinuation, even if he has undergone a successful vasectomy; Refrain from donating blood or sperm for the duration of the study and for 16 weeks (112 days) after the last dose of study treatment
  • Ability to adhere to study visit schedule and understand and comply with all protocol requirements
  • Ability to understand and provide documented informed consent

Exclusion Criteria:

  • Diagnosis of PH WHO Groups 2, 3, 4, or 5
  • Diagnosis of the following PAH Group 1 subtypes: human immunodeficiency virus (HIV)-associated PAH, PAH associated with portal hypertension, schistosomiasis- associated PAH, collagen vascular disease- associated PAH, pulmonary veno-occlusive disease, and pulmonary capillary hemangiomatosis
  • Hgb at screening above gender-specific ULN, per local laboratory test
  • Uncontrolled systemic hypertension as evidenced by sitting systolic BP > 180 mmHg or sitting diastolic BP > 110 mmHg during the Screening Visit after a period of rest
  • Baseline systolic BP < 90 mmHg at screening
  • Pregnant or breastfeeding women
  • Any of the following clinical laboratory values at the Screening Visit: eGFR < 30 mL/min/1.73 m2 (as defined by MDRD equation), serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin levels > 3 × ULN, platelet count < 50,000/mm3 (< 50.0 × 109/L)
  • Currently enrolled in or have completed any other investigational product study within 30 days for small-molecule drugs or within 5 half-lives for investigational biologics prior to the date of documented informed consent
  • Known allergic reaction to sotatercept (ACE-011), its excipients, or luspatercept
  • History of pneumonectomy
  • Pulmonary function test values of forced vital capacity < 60% predicted within 1 year prior to the Screening Visit
  • Stopped receiving any PH chronic general supportive therapy (e.g., diuretics, oxygen, anticoagulants, and digoxin) within 60 days prior to the Screening Visit
  • Initiation of an exercise program for cardiopulmonary rehabilitation within 90 days prior to the Screening Visit or planned initiation during the study (participants who are stable in the maintenance phase of a program and who will continue for the duration of the study are eligible)
  • Untreated more than mild obstructive sleep apnea
  • History of known pericardial constriction
  • History of restrictive cardiomyopathy
  • History of atrial septostomy within 180 days prior to the Screening Visit
  • Personal or family history of long QT syndrome or sudden cardiac death
  • Left ventricular ejection fraction < 50% documented by a historical ECHO or cardiac MRI within the last 12 months prior to screening (if there is more than one assessment of LVEF, the value from the most recent measurement should be used in assessing eligibility)
  • Coronary artery disease (myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or cardiac anginal chest pain) within 6 months prior to the Screening Visit
  • Cerebrovascular accident within 3 months prior to the Screening Visit
  • Acutely decompensated left heart failure within 30 days prior to the Screening Visit, as per investigator assessment
  • Significant (≥ 2+ regurgitation) mitral regurgitation or aortic regurgitation valvular disease
  • Received intravenous inotropes (e.g., dobutamine, dopamine, norepinephrine, and vasopressin) within 30 days prior to the Screening Visit
  • Active malignancy with the exception of fully excised or treated basal cell carcinoma, cervical carcinoma in-situ, or prostate cancer that is not currently or expected, during the study, to be treated with radiation therapy, chemotherapy, and/or surgical intervention, or hormonal treatment.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Sotatercept with addiction medicine services

Sotatercept given in coordination with addiction medicine services

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Treatment response in methamphetamine-associated PAH
Tijdsspanne: 24 weeks

The main hypothesis is that the addition of sotatercept to standard background therapy and addiction medicine services will improve treatment response in meth-APAH, as measured by the echocardiographic parameter TAPSE divided by RVSP (mm/mmHg).

24 weeks

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Jeffrey C Robinson, MD, Oregon Health and Science University

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 december 2026

Primaire voltooiing (Geschat)

1 september 2028

Studie voltooiing (Geschat)

30 november 2028

Studieregistratiedata

Eerst ingediend

6 augustus 2026

Eerst ingediend dat voldeed aan de QC-criteria

11 november 2026

Eerst geplaatst (Werkelijk)

16 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

16 november 2026

Laatste update ingediend die voldeed aan QC-criteria

11 november 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • STUDY00028866
  • 103326 (Ander subsidie-/financieringsnummer: Merck Sharp & Dohme, LLC)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

De-identified data may be shared with qualified investigators upon request. Requests for access should include a brief description of the proposed research objectives, anticipated use of the data, and plans for data security and confidentiality. Data sharing will be considered for researchers with a legitimate scientific purpose, provided the proposed use is consistent with participant consent, applicable regulatory requirements, and institutional policies.

IPD-tijdsbestek voor delen

IPD and supporting information will be available from the date of results publication to ten years post-publication.

IPD-toegangscriteria voor delen

All requests will be reviewed by the Principal Investigator, who will evaluate whether: (1) the proposed use is appropriate and scientifically justified; (2) the requested data are necessary for the stated purpose; (3) the proposed use is consistent with participant consent and IRB requirements; and (4) adequate measures are in place to protect data confidentiality and security. Approved recipients may be required to execute a data use agreement prior to receiving study data.

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • ICF

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

product vervaardigd in en geëxporteerd uit de V.S.

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren